Dr. Marina Udier will join a live session at the 21st BioEquity Europe on Tuesday, May 18, 11:30 am CET.
The Next aCGT Europe Needs to Leapfrog — How? Follow the link below for more details. https://lnkd.in/dpAnmJZ
Nouscom is a next-generation immunotherapy company developing engineered viral vectored vaccines for treatment of cancer. The company has offices, research and manufacturing facilities in Basel, Switzerland and Rome, Italy.
Empowering the immune response
Nouscom’s proprietary immunotherapy platforms utilize a portfolio of uniquely engineered viral vectors optimized for the efficient expression of long strings of tumor neoantigens and comprise a powerful toolkit for the induction of broad and potent anti-tumor T cell responses. The Company’s deep knowledge of vaccine manufacturing, and the platform’s capacity to reliably encode unprecedented numbers of neoantigens is combined with proprietary approaches to neoantigen identification. Our mission is to generate safe, innovative, and potent next-generation cancer immunotherapies that selectively eliminate tumor cells. Our published pre-clinical data indicate that our approach is able to induce strong immune responses with potential to expand the applicability and efficacy of existing immunotherapies while delivering high levels of safety and tolerability (D’Alise et al, 2019).
Enhancing cancer-specific cellular immunity
With a proprietary portfolio of recombinant viral vectors, that redirect and potentiate anti-tumor cellular immunity
to focus on selected immunogenic tumor neoantigens.
They encode an unprecedented number of tumor neoantigens for the induction and boosting of cancer-specific T cells. Nouscom proprietary viral vectors are engineered to encode multiple tumor neoantigens from a patient’s mutanome, expressed at high levels, irrespective of the order in which the neoantigens are assembled. Nouscom cancer vaccines include: a) an off-the-shelf immunotherapy encoding a large number of shared tumor neoantigens that are generated by frameshifts resulting from mismatch repair deficiency (dMMR)/microsatellite instability (MSI) (Leoni et al, 2020), and b) and b) a personalized neoantigen vaccine tailored to individual patient mutanomes.
It is delivered locally or systemically and armored with selected immune-modulators for use in solid tumors.
Our clinical programmes comprise: i) an off-the-shelf’ cancer immunotherapy based on frameshift neoantigens for treatment of mismatch repair deficient (dMMR)/microsatellite instability (MSI) tumors (NOUS-209); and ii) a personalized neoantigen cancer vaccine for treatment of solid tumors (NOUS-PEV).
Find out about our latest press releases and publications and keep updated on our clinical studies.